**Core tip:** We retrospectively reviewed the records of 116 patients with hepatocellular carcinoma (HCC) who underwent surgery between 2008 and 2011 at our hospital. Our results suggest that the factors associated with poor overall survival were alpha-fetoprotein \> 400 ng/mL, tumor size ≥ 5 cm, and high prostaglandin E1 (EP1) receptor expression, but not high cyclooxygenase-2 (COX-2) expression. Disease-free survival did not differ significantly between patients with low or high levels of COX-2 or EP~1~. COX-2 immunoreactivity was significantly higher in well-differentiated HCC tissues (Edmondson grade I-II) than in poorly differentiated tissues (Edmondson grade III-IV) (*P* = 0.003). EP~1~ receptor immunoreactivity was significantly higher in poorly differentiated tissue than in well-differentiated tissue (*P* = 0.001).

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is one of the most aggressive tumors and the third most frequent cause of cancer-related death in the world\[[@B1],[@B2]\]. Although early diagnosis and treatment of HCC have improved substantially, prognosis remains unsatisfactory. HCC often involves highly malignant tumors that respond poorly or not at all to adjuvant systemic and local therapies. This highlights the need for new approaches to prevent and treat the disease.

Two molecules that may be involved in HCC at different stages, and that therefore may be useful for understanding the pathogenesis and progression of the disease, are cyclooxygenase-2 (COX-2) and prostaglandin E1 receptor (EP~1~ receptor). These molecules have already been shown to play important roles in the onset of various cancers, including HCC\[[@B3]-[@B9]\].

COX-2 inhibits apoptosis and increases proliferation in various type of tumors\[[@B10]-[@B12]\]. It also triggers the production of vascular endothelial growth factor and activates metalloproteinases, substantially altering the tumor microenvironment of various cancers\[[@B13]-[@B15]\]. The precise role of COX-2 in HCC remains unclear. Its expression decreases with extent of de-differentiation, and it does not appear to be associated with prognosis\[[@B16]-[@B19]\]. It may be involved in HCC initiation, although direct evidence of this is lacking.

COX-2 catalyzes the conversion of arachidonic acid to prostaglandin E2, which promotes the progression of various types of tumors by binding to the G-protein-coupled EP1 receptor. This led us to wonder whether EP~1~ receptor expression might correlate with HCC progression and might even serve as a prognostic indicator of survival. In fact, in a mouse model of chemically induced colon cancer, administration of selective EP~1~ receptor antagonists or knockout of the EP~1~ receptor gene led to nearly 60% fewer precancerous lesions and a lower overall colon cancer incidence\[[@B20],[@B21]\]. EP~1~ receptor antagonists have also been reported to block the progression of other types of tumor\[[@B22],[@B23]\], including HCC\[[@B18],[@B24]\].

To begin to clarify the potential roles of COX-2 and EP~1~ receptor in HCC, and to determine the potential prognostic value of EP~1~ receptor expression, we examined relative expression levels in tissues taken from HCC patients treated at our hospital, and correlated these levels with survival.

MATERIALS AND METHODS
=====================

This research was approved by the Ethics Committee of the Tumor Hospital of Guangxi Medical University, and patients provided informed consent for their data and tissue to be used for research purposes when they were admitted for treatment at our hospital.

Patients
--------

This study was a retrospective analysis of HCC patients treated by curative hepatectomy at the Tumor Hospital of Guangxi Medical University between May 2008 and May 2011. To be included in our study, patients needed to have pathology-confirmed HCC and no history of antitumor therapies before hepatic resection. They also needed to satisfy the following curative hepatectomy criteria: (1) the tumor removed by hepatectomy was solitary; (2) the surgery margin was greater than 1 cm; (3) there was no residual tumor\[[@B25]\], portal tumor thromboses\[[@B26]\] or extrahepatic metastases based on post-surgical imaging; and (4) patients with high levels of alpha-fetoprotein (AFP) before surgery had normal levels within two months after surgery. Patients were excluded from the study if they had multiple tumors, extrahepatic metastases or macroscopic intrahepatic metastases adjacent to the primary tumor.

Follow-up
---------

All HCC patients were followed up 1 mo after resection, then at 3-mo intervals in the first year, and then at 3-6 mo intervals thereafter until 60 mo after resection or death. During each follow-up visit, routine investigations including AFP level, liver function, chest X-ray, ultrasound, CT or MRI were conducted.

Immunohistochemistry of COX-2 and EP~1~ receptor
------------------------------------------------

Tumor specimens were fixed in 10% formalin, embedded in paraffin, cut into 3-μm sections, de-paraffinized with xylene and rehydrated by decreasing concentrations of ethanol. Antigen retrieval was performed for 10 min at 95 °C in citrate buffer (pH 6.0) in a microwave oven. Sections were immersed in 3% hydrogen peroxide for 15 min to block endogenous peroxidases, then incubated at 37 °C for 1 h with rabbit anti-human COX-2 polyclonal antibody (1:400; Abcam, United Kingdom) or rabbit anti-human EP~1~ receptor polyclonal antibody (1:200; Abcam). The sections were rinsed in phosphate-buffered saline (PBS), incubated with biotinylated anti-rabbit immunoglobulin for 20 min at room temperature, and then rinsed again with PBS. The sections were incubated with anti-horseradish peroxidase conjugate for 10 min, rinsed with PBS, and incubated with diaminobenzidine for 10 min. Finally, the sections were counterstained with hematoxylin. As a negative control, tissues were treated as described above, except they were incubated with PBS instead of primary antibodies.

Immunohistochemical staining results were independently evaluated by three authors (Hao-Jie Yang, Zhe Guo and Yu-Ting Yang) and an experienced hepatopathologist (Chun-Jun Li) from the Department of Pathology of Guangxi Tumor Hospital. The percentages of cells positive for COX-2 or EP~1~ receptor as well as relative staining intensity were determined. Percentages of positive cells were categorized as follows: 0 (no positive tumor cells), 1 (1%-25% positive), 2 (26%-50% positive), 3 (51%-75% positive), and 4 (76%-100% positive). Staining intensity was categorized as follows: 0 (no staining), 1 (weak, light yellow), 2 (moderate, yellow-brown), and 3 (strong, brown)\[[@B27]\]. The scores for positive cell percentages and for staining intensity were multiplied together to yield a single immunohistochemical staining index from 0 to 12. Sections with an index of 0-5 were defined as showing low expression, while those with an index of 6-12 were defined as showing high expression.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 19.0 (IBM, United States). Inter-group differences in categorical variables were assessed for significance using the χ^2^ test; differences in continuous variables were assessed using the Mann-Whitney *U* test or *t*-test. OS and DFS were analyzed using the Kaplan-Meier method, and differences between curves were assessed for significance using the log-rank test. Multivariate Cox proportional hazards modeling was used to identify independent prognostic factors. The threshold for significance was defined as *P* \< 0.05.

RESULTS
=======

Patient characteristics
-----------------------

During the study, 748 patients with HCC were scheduled for hepatectomy in my center. Of these, 221 (29.5%) were excluded as they had received initial HCC treatment in other hospitals. Of the remaining 527 patients, 161 (30.5%) had solitary nodular tumors without portal tumor thromboses or extrahepatic metastases. We excluded 33 (20.4%) because they underwent only transarterial chemoembolization, local ablation therapy, or ethanol injection, and we excluded 12 (7.4%) as they lacked complete follow-up data. In total, 116 (72%) patients were included in the final analysis (93 men, 23 women) with a median age of 67 (range, 39-83) (Table [1](#T1){ref-type="table"}). Immunohistochemistry showed low COX-2 expression in 62 patients (53.4%) and low EP~1~ receptor expression in 73 (62.9%).

###### 

Clinicopathological characteristics of 116 hepatocellular carcinoma patients treated by curative resection, stratified by COX-2 and EP~1~ receptor expression

  **Variable**               **COX-2**            ***P* value**       **EP~1~ receptor**   ***P* value**                            
  -------------------------- -------------------- ------------------- -------------------- -------------------- ------------------- -------
  Gender, M/F                48/14                45/9                0.426                60/13                33/10               0.477
  Age (yr)                   46.9 ± 10.8          47.9 ± 11.5         0.308                46.6 ± 11.1          47.3 ± 11.2         0.486
  HbsAg                                                                                                                             
  Negative                   10                   10                  0.734                11                   9                   0.420
  Positive                   52                   44                                       62                   34                  
  Liver cirrhosis                                                                                                                   
  No                         10                   10                  0.734                14                   6                   0.472
  Yes                        52                   44                                       59                   37                  
  AFP (ng/mL)                                                                                                                       
  \< 400                     41                   44                  0.062                56                   29                  0.276
  ≥ 400                      21                   10                                       17                   14                  
  Edmondson grade                                                                                                                   
  I-II                       26                   37                  0.004                46                   17                  0.014
  III--IV                    36                   17                                       27                   26                  
  Child-Pugh class                                                                                                                  
  A                          43                   48                  0.773                60                   31                  0.201
  B                          11                   14                                       13                   12                  
  Tumor capsule                                                                                                                     
  Complete                   37                   34                  0.717                44                   27                  0.788
  Incomplete                 25                   20                                       29                   16                  
  Tumor size (cm)            5.7 (3-7)            6.6 (4-8.6)         0.134                5 (3.5-7)            6 (3.7-8.5)         0.207
  Albumin (g/L)              41.1 ± 4.4           40.4 ± 4.6          0.434                41.5 ± 4.3           40.2 ± 4.5          0.134
  Platelet count (10^9^/L)   167.9 (107.3-205.3   186.6 (136.3-230)   0.136                178.9 (107.3-205.3   186.6 (136.3-230)   0.833
  AST (U/L)                  56.6 (28.3-61)       55.6 (27-60)        0.924                38 (27-60)           44 (30.5-61.5)      0.737
  ALT (U/L)                  54.8 (28-56)         62.7 (24.8-57.9)    0.539                37(27-56)            38(27-55)           0.917
  Total bilirubin (μmol/L)   14.08 (8.9-18.4)     14.3 (9.4-15.3)     0.912                11.9(9.35-16.6)      13.4(9-17.7)        0.580

AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HBsAg: Hepatitis B surface antigen.

EP~1~ receptor expression is a prognostic predictor of OS
---------------------------------------------------------

OS was significantly lower among patients with high expression of EP~1~ receptor than among those with low expression (Figure [1](#F1){ref-type="fig"}). OS did not differ significantly between patients with low or high COX-2 expression. DFS did not differ significantly between patients with low or high expression of COX-2 or EP~1~ receptor.

![Overall survival of hepatocellular carcinoma patients stratified by low or high expression of EP~1~ receptor.](WJG-22-8798-g001){#F1}

The Cox hazards model showed 3 independent predictors of poor OS: tumor size ≥ 5 cm, high expression of EP~1~ receptor and AFP ≥ 400 ng/mL (Table [2](#T2){ref-type="table"}).

###### 

Multivariable analysis to identify predictors of overall survival in 116 hepatocellular carcinoma patients

  **Factors**                **Hazard ratio**   **95%CI**     ***P* value**
  -------------------------- ------------------ ------------- ---------------
  AFP ≥ 400 ng/mL            1.691              1.094-2.614   0.018
  Incomplete tumor capsule   0.979              0.659-1.454   0.915
  Tumor size ≥ 5 cm          1.582              1.027-2.438   0.038
  Edmondson grade III--IV    1.149              0.663-1.992   0.621
  EP1 receptor expression    2.318              1.190-4.516   0.014

AFP: Alpha-fetoprotein.

COX-2 and EP~1~ receptor expression correlates with tumor differentiation
-------------------------------------------------------------------------

COX-2 immunoreactivity was significantly higher in well-differentiated HCC tissues (Edmondson grade I-II) than in poorly differentiated tissues (Edmondson grade III-IV) (*P* = 0.003). EP~1~ receptor immunoreactivity was significantly higher in poorly differentiated tissue than in well-differentiated tissue (Figure [2](#F2){ref-type="fig"}; *P* = 0.001). Figure [3](#F3){ref-type="fig"} shows representative examples of different staining results in tissues of different histology grade.

![Cyclooxygenase-2 and prostaglandin E1 receptor immunoreactivity scores in hepatocellular carcinoma tissues at different histological grades. Cyclooxygenase-2 (COX-2) expression was higher in well-differentiated tissue (Edmondson grade I-II), while EP~1~ receptor expression was higher in poorly-differentiated tissue (Edmondson grade III-IV). WD: Well-differentiated; PD: Poorly differentiated; HCC: Hepatocellular carcinoma.](WJG-22-8798-g002){#F2}

![Representative micrographs showing different intensities of immunohistochemical stain against cyclooxygenase-2 and prostaglandin E1 receptor in tissues with different histological grades (Edmondson grade I-IV). Magnification, × 100. Cyclooxygenase-2 (COX-2) expression level decreased with lower grade of differentiation, while EP~1~ receptor expression increased with lower grade of differentiation.](WJG-22-8798-g003){#F3}

DISCUSSION
==========

HCC is one of the most aggressive tumors and has a poor prognosis. Some patients can undergo curative resection, but this treatment is associated with a high rate of intrahepatic recurrence. Most patients with HCC are ineligible for resection because their disease has already reached an advanced stage by the time it is diagnosed. These patients are treated with local or systemic adjuvant modalities that provide only short-term regression, stabilization, or symptomatic control. Therefore, new therapeutic strategies are needed to improve long-term survival.

Our results indicate that the EP~1~ receptor is involved in HCC progression, suggesting that it may be a reasonable therapeutic target. High expression of the EP~1~ receptor was associated with poor prognosis in our patients, and expression was significantly higher in poorly differentiated tissue than in well-differentiated tissue. The observed correlation between higher expression and poorer differentiation is consistent with a previous study\[[@B18]\]. These results suggest that targeting the EP~1~ receptor may provide a more selective approach to treating HCC than using COX inhibitors to block prostaglandin E2 synthesis, which increases the risk of cardiovascular events\[[@B28]\].

Although studies have associated COX-2 expression with differentiation, invasion and metastasis in HCC\[[@B3],[@B18],[@B24]\], it has not been linked with survival. In the present study, we failed to find an association between COX-2 expression and survival when patients were dichotomized into groups with low or high expression. While it is possible that a more quantitative approach may identify associations between COX-2 levels and survival, we believe it is more likely that expression of COX-2 may be important only during initiation of HCC, whereas the EP~1~ receptor, which is the downstream target of prostaglandin E2 generated by COX-2, may be involved in disease progression. This may explain why we observed a different relationship between the expression of COX-2 and EP~1~ receptor: patients with high expression of one showed low expression of the other. This may also explain why we found that expression of the EP~1~ receptor, but not the COX-2 receptor, predicted OS in our cohort.

Several factors may help to explain why high expression of the EP~1~ receptor predicts poor survival. The receptor enhances tumor cell proliferation, invasion and migration\[[@B4],[@B6],[@B29],[@B30]\], as well as adaptation to hypoxic conditions\[[@B6],[@B31]\]. The receptor has also been reported to inhibit immune function and promote tumor progression\[[@B32]\]. The EP~1~ receptor can even induce prostaglandin E2 production by binding to the receptor of Fas ligand\[[@B32]-[@B34]\].

This study has some limitations. Firstly, the authors used only an HE method, therefore more accurate and quantitative methods, such as Western blot, polymerase chain reaction *etc*., should be applied in future studies. Secondly, it is known that other cytokines, except COX-2 and EP1, have been reported to be strongly associated with HCC. These cytokines may be involved in different aspects of the pathogenesis of HCC and should be explored as a network pattern in future studies.

In conclusion, our results suggest that COX-2 expression correlates with an early event during the initiation of HCC, while EP~1~ receptor expression plays an important role in tumor progression and predicts OS.

COMMENTS
========

Background
----------

Hepatocellular carcinoma (HCC) is one of the most aggressive tumors and the third most frequent cause of cancer-related death in the world. Although early diagnosis and treatment of HCC have improved substantially, prognosis remains unsatisfactory. HCC often involves highly malignant tumors that respond poorly or not at all to adjuvant systemic and local therapies. This highlights the need for new approaches to prevent and treat the disease.

Research frontiers
------------------

Two molecules that may be involved in HCC at different stages, and that therefore may be useful for understanding the pathogenesis and progression of the disease, are cyclooxygenase-2 (COX-2) and prostaglandin E1 receptor (EP~1~ receptor). These molecules have already been shown to play important roles in the onset of various cancers, including HCC.

Innovations and breakthroughs
-----------------------------

The authors retrospectively reviewed the records of 116 patients with HCC who underwent surgery between 2008 and 2011 at their hospital, and found that COX-2 expression appears to be linked to early HCC events (initiation), while EP~1~ receptor expression may participate in tumor progression and predict survival.

Applications
------------

These results suggest that targeting the EP~1~ receptor may provide a more selective approach to treating HCC than using COX inhibitors to block prostaglandin E2 synthesis, which increases the risk of cardiovascular events.

Terminology
-----------

Percentages of positive cells were categorized as follows: 0 (no positive tumor cells), 1 (1%-25% positive), 2 (26%-50% positive), 3 (51%-75% positive), and 4 (76%-100% positive). Staining intensity was categorized as follows: 0 (no staining), 1 (weak, light yellow), 2 (moderate, yellow-brown), and 3 (strong, brown). The scores for positive cell percentages and for staining intensity were multiplied together to yield a single immunohistochemical staining index from 0 to 12. Sections with an index of 0-5 were defined as showing low expression, while those with an index of 6-12 were defined as showing high expression.
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